Table 1:

Clinical and demographic characteristics of the cohort

	Total (n=97)	Metastatic (n=51)	Localized cancer (n=46)	Difference
	M (SD)	M (SD)	M (SD)
Age (years)	57.21 (13.2)	57.6 (13.3)	56.84 (13.2)	t=−.276, p=.78
Anxiety (GAD-7)	11.18 (6.3)	10.82 (6.7)	11.56 (5.9)	t=.584, p=.56
Depression (PHQ-9)	12.17 (6.6)	11.47 (6.6)	12.9 (6.7)	t=1.075, p=.29
Time from blood draw (days)	22.4 (37.2)	16.3 (23.3)	30.3 (48.8)	t=1.669, p=.10
Albumin	3.94 (.43)	3.82 (.44)	4.10 (.36)	t=3.180, p=.002
ANC	4.92 (4.6)	5.28 (5.65)	4.42 (2.9)	t=−.857, p=.394
ALC	1.48 (1.1)	1.64 (1.30)	1.26 (.64)	t=−1.823, p=.07
NLR	5.84 (8.7)	5.00 (5.76)	6.98 (11.6)	t=1.058, p=.29
	N (%)	N (%)	N (%)
Gender
• Male	35 (35%)	18 (35%)	16 (35%)	χ2=.004, p=.95
• Female	65 (65%)	33 (64%)	30 (65%)
Disease Type
• Solid Tumors	76 (78%)	34 (68%)	41 (89%)	χ2=10.622, p=.001
• Heme malignancy	21 (22%)	16 (32%)	5 (11%)
Time of Blood Draw
Before appt	63 (63%)	34 (67%)	28 (61%)	χ2=.358, p=.55
After appt	37 (37%)	17 (33%)	18 (39%)
Blood draw within a week?
• Yes	45 (45%)	27 (53%)	17 (37%)	χ2= .266, p=.61
• No	55 (55%)	24 (47%)	29 (63%)
Meets Depression Screening (PHQ-9D≥10)
• Yes	62 (62%)	29 (57%)	31 (67%)	χ2 =1.01, p=.32
• No	38 (38%)	22 (43%)	15 (33%)
Meets Anxiety Screening (GAD-7≥10)
• Yes	60 (60%)	31 (61%)	27 (59%)	χ2=.027, p=.87
• No	40 (40%)	20 (39%)	19 (41%)
Taking Psychotropic (prior to initial visit)
• Yes	69 (69%)	32 (65%)	35 (76%)	χ2= 1.904, p=.17
• No	31 (31%)	19 (35%)	11 (24%)
Taking Antidepressant (prior to initial visit)
• Yes	38 (38%)	18 (64%)	19 (41%)	χ2 = .324, p=.57
• No	62 (62%)	33 (35%)	27 (59%)
Plan to Start or Increase Antidepressant
• Yes	45 (45%)	23 (45%)	21 (45%)	χ2<.001, p=.98
• No	55 (55%)	28 (55%)	25 (55%)